Understanding Adverse Events

Similar documents
GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

Adverse Events in Clinical Trials: Definitions and Documentation

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute

CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives

IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others

PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE

Data Management in Clinical Trials

Clinical Trials and Safety Surveillance of Drugs in Development

GUIDELINES ON MEDICAL DEVICES

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Medicine Safety Glossary

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis

Guideline on good pharmacovigilance practices (GVP)

Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5

Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.

A New Standard for Medical Device Adverse Event Classification

The Trans-Tasman Early Warning System. Processes in Australia and New Zealand

CONTENTS SECTION TITLE PAGE

Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions

POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D

ABSTRACT INTRODUCTION PATIENT PROFILES SESUG Paper PH-07

Adverse Events: Documenting, Recording, and Reporting

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Guidance for Industry and Investigators

Vertex Investigator-Initiated Studies Program Overview

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) Annotated with TGA comments

Guideline for Industry

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes

TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES FOR INSURANCE AND INDEMNITY OF CLINICAL TRIALS IN TANZANIA

Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools

Standard Operating Procedure for the Recording, Management and Reporting of Adverse Events by Investigators

Guidance for Clinical Investigators, Sponsors, and IRBs

INVESTIGATOR AGREEMENT: This page should follow the protocol approval page. Sample text is provided in Appendix C.

Data Management Unit Research Institute for Health Sciences, Chiang Mai University

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

Effective Date: October 2015

Things You Should Know About Adverse Event Report Data

STANDARD OPERATING PROCEDURES FOR GOOD CLINICAL PRACTICE

PHARMACOVIGILANCE GUIDELINES

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

Quality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work

Application Guide Global Awards in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Research

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

GOOD CLINICAL PRACTICE*)

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

Questions and Answers to the Annual Safety Report

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

WM: Managing the Side Effects of Treatment

Guidance for Industry

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Page 191 TITLE 21 FOOD AND DRUGS 355 1

Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance

42 CFR (F309) QUALITY OF CARE. Changes to Interpretive Guidance. Training Objectives. *Overview of changes

ABSTRACT On October 1st, 2008, CDASH released the first 16 common CRF streams (or domains) for use by the Pharmaceutical Industry.

MedDRA in clinical trials industry perspective

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus Assay. June 17, 2016

ICH Topic E 6 (R1) Guideline for Good Clinical Practice. Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95)

STAR*D: Sequenced Treatment Alternatives to Relieve Depression Data Collection Procedures for Cognitive Therapists

Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations

Guidance on adverse drug reactions

COMPENSATION FORMULA

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

SYNOPSIS. Risperidone: Clinical Study Report CR003274

ICH Topic E 6 Guideline for Good Clinical Practice NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) *

THE CLINICAL TRIALS BILL (No. XIX of 2010) Explanatory Memorandum

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

INTERIM SITE MONITORING PROCEDURE

DATE DUE: RESIDENT NAME: DATE(S) OF COMPLETION: STAFF COMPLETING RESIDENT REVIEW:

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8

Guideline for good clinical practice E6(R2)

Questions and answers on serious non-fatal adverse events and reporting rules

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations

TEMPLATE DATA MANAGEMENT PLAN

Leukapheresis for inflammatory bowel disease

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Emergency Room Treatment of Psychosis

Guidance notes on the management of adverse events and product complaints from digital media

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH

Administrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Quality Monitoring Checklist

United States Department of Health and Human Services Findings on the Permissibility of Reporting to Public Health Authorities under HIPAA

Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications / database systems

DRAFT FORMULA TO DETERMINE THE QUANTUM OF COMPENSATION IN CASE OF CLINICAL TRIAL RELATED INJURY (OTHER THAN DEATH)

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

Guidance for Industry Migraine: Developing Drugs for Acute Treatment

Colon Cancer. What Is Colon Cancer? What Are the Screening Methods?

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required

Transcription:

The Fundamentals of International Clinical Research Understanding Adverse Events Tracy Newbold Family Health International

Reason for Adverse Event Collection and Reporting The most important responsibilities of investigators and sponsors of clinical research studies: Protection of human subjects. Collection of clean and reproducible data.

Goals of the Presentation UNDERSTANDING: Definition of Adverse Event Expected vs. Unexpected Adverse Event Definition of SERIOUS Adverse Events Intensity vs. Seriousness of Adverse Events Relationship of Adverse Event to Study Product Reporting of Adverse Events

What is an Adverse Event (AE)? Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. (ICH-E2A)

What is an Adverse Event (AE)? Any unfavorable and unintended sign (including an abnormal lab finding) Symptom or disease, temporally associated with use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product (ICH-E2A)

What is an Adverse Event (AE)? Unfavorable deviation from baseline health, which includes: Worsening of conditions present at onset of the study Patient deterioration due to primary disease Intercurrent illness Events related or possibly related to concomitant medications

What is an Adverse Event (AE)? Unwanted Effects Symptoms (headache, nausea) Syndromes of disease Physical findings (elevated BP, lump) Abnormal lab values Overdoses Toxicities

Expected vs Unexpected AE An expected AE is any adverse reaction whose nature and intensity have been previously observed and documented for the study product (e.g. in the investigator brochure, product information).

Expected vs Unexpected AE An unexpected AE is any adverse reaction not observed,, whether or not it has been anticipated because of the pharmacologic properties of the study agent. Unexpected adverse drug experience: Any adverse drug experience, the specificity or severity of which is not previously consistent with the current investigator brochure; or, if an investigator brochure is not required or available, the specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. 21 CFR 312.32

How Would You Describe an AE? Wherever possible, adverse events should be described in terms of a change in the status of patient s s health, NOT the action taken or outcome.

How Would You Describe an AE? Example: A patient experiences a bleeding stomach ulcer that requires hospitalization. Question: What event(s) should be listed on the Case Report Form (CRF)? Answer: Bleeding ulcer

What Is a Serious Adverse Event? A SERIOUS Adverse Event (SAE) is defined as an AE meeting one of the following conditions: Death during the period of protocol defined surveillance Life threatening (defined as a subject at immediate risk of death at the time of the event)

What is a Serious Adverse Event? Hospital admission during the period of protocol defined surveillance Any event that results in congenital anomaly or birth defect Any event that results in a persistent or significant disability/incapacity

What is a Serious Adverse Event? Any other important medical event that may not result in death, be life threatening, or require hospitalization, may be considered a serious adverse event when,, based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.

Intensity of the Adverse Event All adverse events will be assessed by the investigator using the protocol defined grading system. If the protocol has no defined grading system, then guidelines such as the following will be used to quantify intensity:

Intensity of the Adverse Event Mild: Transient or mild discomfort (<48 hours); no medical intervention/therapy required Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required

Intensity of the Adverse Event Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible Life threatening: Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care possible

Serious vs Severe Serious: Serious is defined as a regulatory definition Severe: Severe is defined as an intensity classification (mild, moderate, severe)

Adverse Event Relationship to Study Products All AEs must have their possible relationship to study product assessed by a system such as the following:

Adverse Event Relationship to Study Products Associated The event is temporally related to the administration of the study product and no other etiology explains the event. Not Associated - The event is temporally independent of study product and/or the event appears to be explained by another etiology.

Reporting Adverse Events Non-serious AEs ROUTINE REPORTING (e.g. annual report, AE form, CRF)

Reporting Adverse Events ANY Serious AE Complete DMID SAE form and send to PPD or send to DMID via PPD For fatal/ life-threatening SAEs: Within 24 hours of site awareness For all other SAEs: Within 72 hours (3 days) of site awareness ROUTINE REPORTING (e.g. annual report)

Goals of the Presentation Definition of AE Expected vs. Unexpected AE Definition of SERIOUS AE Intensity vs. Seriousness of AEs Relationship of AE to Study Product Reporting of AEs Achieved?

Breakout Session Does the scenario constitute an AE? If yes, is it an SAE? Why or why not? For AEs,, please discuss the following: Intensity Relatedness Site responsibilities Reporting Clinical follow-up